Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 19, 2016, Pages E2646-E2654

  Sockolosky, Jonathan T ^a   Dougan, Michael ^b,c,d   Ingram, Jessica R ^b,c   Ho, Chia Chi M ^a,e   Kauke, Monique J ^b,f   Almo, Steven C ^g   Ploegh, Hidde L ^a,b,c   Garciaa, K Christopher ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Stanford University   (United States)

^f Massachusetts Institute of Technology Cambridge   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer|macrophage; Immunotherapy; Protein engineering; T cell

Indexed keywords

10F 9G 2; CANCER ANTIBODY; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MIAP 301; MONOCLONAL ANTIBODY; NANOBODY; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD47 ANTIGEN;

ADAPTIVE IMMUNITY; ALPACA; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CELL SURFACE; CONTROLLED STUDY; CROSS REACTION; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MACROPHAGE; MALE; MELANOMA; MONOTHERAPY; MOUSE; MOUSE MODEL; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SPECIES DIFFERENCE; SURFACE PLASMON RESONANCE; TUMOR CELL INOCULATION; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; DRUG EFFECTS; FEMALE; IMMUNIZATION; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD47; ANTINEOPLASTIC AGENTS; CANCER VACCINES; FEMALE; IMMUNIZATION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; TREATMENT OUTCOME;

EID: 84966270767     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1604268113     Document Type: Article

References (46)

1. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252-264.
2. DiLillo DJ, Ravetch JV (2015) Differential Fc-receptor engagement drives an antitumor vaccinal effect. Cell 161(5):1035-1045.
3. Park S, et al. (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2):160-170.
4. Zhu EF, et al. (2015) Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27(4):489-501.
5. Ho CCM, et al. (2015) Velcro engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem 290(20):12650-12663.
6. Barclay AN, Van den Berg TK (2014) The interaction between signal regulatory protein alpha (SIRPα) and CD47: Structure, function, and therapeutic target. Annu Rev Immunol 32:25-50.
7. Tsai RK, Discher DE (2008) Inhibition of self engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180(5):989-1003.
8. Chao MP, Majeti R, Weissman IL (2011) Programmed cell removal: A new obstacle in the road to developing cancer. Nat Rev Cancer 12(1):58-67.
9. Jaiswal S, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138(2):271-285.
10. Chao MP, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142(5):699-713.
11. Weiskopf K, et al. (2013) Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341(6141):88-91.
12. Theocharides APA, et al. (2012) Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. J Exp Med 209(10): 1883-1899.
13. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138(2):286-299.
14. Tseng D, et al. (2013) Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 110(27):11103-11108.
15. McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways: Activating T cells after cancer cell phagocytosis from blockade of CD47 don't eat me signals. Clin Cancer Res 21(16):3597-3601.
16. Liu X, et al. (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21(10):1209-1215.
17. Dahan R, et al. (2015) FcaγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28(3):285-295.
18. Willingham SB, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109(17):6662-6667.
19. Maute RL, et al. (2015) Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 112(47):E6506-E6514.
20. De Meyer T, Muyldermans S, Depicker A (2014) Nanobody-based products as research and diagnostic tools. Trends Biotechnol 32(5):263-270.
21. Zhao XW, et al. (2011) CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108(45): 18342-18347.
22. Akkaya M, Aknin M-L, Akkaya B, Barclay AN (2013) Dissection of agonistic and blocking effects of CD200 receptor antibodies. PLoS One 8(5):e63325.
23. Yang X, et al. (2013) Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 21(1):91-100.
24. Barclay AN, Brown MH (2006) The SIRP family of receptors and immune regulation. Nat Rev Immunol 6(6):457-464.
25. Hoek RM, et al. (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290(5497):1768-1771.
26. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL (2012) Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 12(11):786-798.
27. Peyvandi F, et al.; TITAN Investigators (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511-522.
28. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190(3):355-366.
29. Dougan M, et al. (2010) IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med 207(10):2195-2206.
30. Mahoney KM, Rennert PD, Freeman GJ (2015) Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14(8):561-584.
31. Overwijk WW, et al. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569-580.
32. Abès R, Gélizé E, Fridman WH, Teillaud J-L (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116(6):926-934.
33. Reinhold MI, Lindberg FP, Kersh GJ, Allen PM, Brown EJ (1997) Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med 185(1):1-11.
34. Yi T, et al. (2015) Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity 43(4):764-775.
35. Seiffert M, et al. (2001) Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97(9):2741-2749.
36. Ticchioni M, et al. (1997) Integrin-associated protein (CD47) is a comitogenic molecule on CD3-activated human T cells. J Immunol 158(2):677-684.
37. Kwong LS, Brown MH, Barclay AN, Hatherley D (2014) Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity: Implications for engraftment of human cells. Immunology 143(1):61-67.
38. Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24(2):225-232.
39. Chao MP, et al. (2010) Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2(63):63ra94.
40. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163-189.
41. Furuta J, Inozume T, Harada K, Shimada S (2014) CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. JInvestDermatol134(5):1369-1377.
42. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP (2008) Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 181(11):8120-8132.
43. Soto-Pantoja DR, et al. (2014) CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74(23): 6771-6783.
44. Albanesi M, et al. (2013) Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122(18):3160-3164.
45. Lahoud MH, et al. (2006) Signal regulatory protein molecules are differentially expressed by CD8- dendritic cells. J Immunol 177(1):372-382.
46. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB (2007) Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods 324(1-2):13-25.